Related Experiment Video
Updated: Jun 4, 2026
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor
Qi Zhang1, Jiaying Wu1, Fankai Meng1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in cancer treatment that can induce durable remission in patients with hematological malignancies who have failed prior therapies. As the use of CAR-T cell therapy increases, treatment-related renal complications deserves careful attention, particularly in patients with a solitary kidney, in whom renal complications may further increase clinical risk. Here, we report the case of a living kidney donor who was diagnosed with diffuse large B-cell lymphoma (DLBCL). After CAR-T cell therapy, the patient developed only mild cytokine release syndrome (CRS), without signs of acute kidney injury or renal impairment, and subsequently achieved a favorable metabolic response approaching complete remission.
